Basic Verampil Information

• INN (International Nonproprietary Name): Verapamil
• Brand Names Available In Canada (English): Isoptin, Isoptin SR, and generics labelled as Verapamil; other global brands include Calan/Calan SR and Verelan (availability varies by supplier).
• ATC Code: C08DA01
• Forms & Dosages: Tablets 40 mg, 80 mg, 120 mg; Extended‑Release 120 mg, 180 mg, 240 mg, 360 mg; ER Capsules 100–360 mg; IV solution 2.5 mg/mL in 2 mL or 5 mL ampoules.
• Manufacturers In Canada (English): Viatris (formerly Mylan), Teva, Abbott (Isoptin), Pfizer (Calan) and other regional generic suppliers.
• Registration Status In Canada (English): Approved by Health Canada for prescription use.
• OTC / Rx Classification: Prescription (Rx) only in most territories.

Latest Research Highlights — Canadian & International

What is new in verapamil research from 2022 to 2025 and what it means for patients in Canada?

Recent trials and cohort studies continue to support verapamil’s established uses in supraventricular tachycardia (SVT) and ventricular rate control for atrial fibrillation and flutter.

Canadian cohort data and international randomized controlled trials report acute rate control efficacy comparable to diltiazem, with a higher frequency of constipation and bradycardia noted in verapamil arms.

Extended‑release formulations in several studies improved adherence by enabling once‑daily dosing compared with immediate‑release three‑times‑daily regimens.

Smaller randomized trials examined verapamil for migraine prevention; results are mixed and not yet practice‑changing for primary care in Canada.

Ongoing Canadian registry work is evaluating extended‑release formulations’ impact on adherence in rural populations and whether emergency departments prescribe ER products differently after discharge.

Data highlights: ATC C08DA01 confirms class and mechanism, and the World Health Organization lists verapamil as an essential medicine.

Patient‑centred note: newer evidence prioritizes tolerability in elderly and comorbidity‑heavy cohorts common in Canadian primary care.

• Adverse Events Frequency: constipation, bradycardia, dizziness, edema and nausea were the most commonly reported side effects.
• Trial Limitations: small sample sizes for migraine studies, heterogenous ER formulations, and limited rural representation in RCT enrolment.

Clinical Effectiveness In Canada — Health Canada & Formularies

How does verapamil perform within Canadian regulatory and formulary systems?

Health Canada has approved verapamil for prescription use and product monographs and DIN‑labelled packaging are recorded in national drug databases.

Clinical effectiveness in Canada aligns with international guidelines for hypertension, angina and arrhythmia management when used according to monographs.

Provincial formularies such as Ontario Drug Benefit, BC PharmaCare and RAMQ include verapamil or equivalent non‑dihydropyridine agents on varying tiers; local coverage rules and DIN checks are necessary.

• Typical Clinical Endpoints Monitored In Canada: blood pressure control, angina frequency, and ventricular rate during arrhythmia.

Evidence note: verapamil is extensively metabolized by the liver and product data advise dose reduction in hepatic impairment.

Patient access note: pharmacists at community chains and clinics can confirm DIN, coverage and bilingual monographs in English and French.

Indications & Expanded Uses (Approved Versus Off‑Label)

What is approved and what is off‑label when clinicians consider verapamil?

Approved Indication

Hypertension, angina pectoris and supraventricular arrhythmias with IV use for acute rhythm conversion (2.5–10 mg slow IV bolus) and oral ER formulations for maintenance; typical adult dosing as per product monographs.

Off‑Label Use

Migraine prophylaxis and some paediatric acute SVT applications are used in practice but often off‑label in Canada; clinicians should document rationale and counsel patients.

Pediatric Use

Pediatric use is specialist‑led with weight‑based dosing, primarily for acute SVT using IV formulations under cardiology guidance.

Cultural note: Canadian patients expect clear consent and bilingual information for off‑label prescribing, and rural primary care often refers complex IV protocols to cardiology or paediatrics.

Composition & Brand Landscape

What formulations and brands should Canadian patients expect to see on pharmacy shelves?

Active ingredient: verapamil, a phenylalkylamine calcium‑channel blocker with ATC C08DA01 classification.

• Major Canadian Suppliers: Viatris (formerly Mylan), Teva, Abbott (Isoptin), Pfizer (Calan).
• Common Pack Sizes: 30s, 60s and 100s for tablets and capsules; single‑use ampoules for IV.

Practical note: generics are commonly stocked in urban pharmacies, while some regional branches of Jean Coutu, London Drugs, Shoppers Drug Mart and Rexall may carry brand or specific pack sizes by demand.

Contraindications & Special Precautions

Who should not take verapamil, and what should be watched for?

• Absolute Contraindications: severe hypotension (<90 mmHg systolic), advanced AV block unless pacemaker present, sick sinus syndrome without pacemaker, cardiogenic shock, decompensated heart failure, Wolff‑Parkinson‑White syndrome with atrial fibrillation, or documented hypersensitivity to verapamil or excipients.
• Relative Cautions: hepatic impairment (reduce dose), bradycardia or conduction defects, concomitant beta‑blocker or digoxin therapy, pregnancy and breastfeeding considerations.

Canadian context: older adults and patients in remote or Indigenous communities frequently present with multimorbidity and polypharmacy, increasing the importance of careful review of conduction status and blood pressure before dispensing.

Emergency Signs Requiring Urgent Care: severe hypotension, profound bradycardia, syncope, confusion or signs of cardiogenic shock.

Dosage Guidelines — Standard & Adjustments

What are standard starting doses and how should verapamil be adjusted in special populations?

• Titration Steps: increase gradually to clinical effect while monitoring blood pressure and heart rate.
• Monitoring: baseline ECG if conduction disease suspected, regular BP and HR checks during initiation and titration.

Provincial practice note: some formularies promote ER products to improve adherence; pharmacists can recommend switching where coverage and DIN permit.

Patient instruction: take certain formulations with food as directed and do not crush extended‑release tablets or capsules.

Interactions Overview — Drugs & Foods

Which medications and foods interact with verapamil and what actions should pharmacists take?

Major Interactions

Additive AV nodal suppression with beta‑blockers and some antiarrhythmics; increased digoxin levels when used concurrently; CYP3A4 inhibitors can raise verapamil plasma concentrations.

Food Interaction

Grapefruit juice inhibits CYP3A4 and may elevate verapamil exposure; advise patients to avoid grapefruit and grapefruit products.

Minor / Monitor Closely

Alcohol may enhance hypotensive and dizziness effects; co‑medications that prolong PR interval require monitoring.

• Interaction Severity Definitions: major — avoid; moderate — monitor and adjust dose; minor — counsel and observe.
• Recommended Actions: screen DIN at dispensing, advise on grapefruit avoidance, and arrange follow‑up for HR/BP checks if combined with interacting drugs.

Cultural Perceptions & Patient Habits

What do Canadian patients worry about when they see verapamil on a prescription?

Common online searches use brand names such as Isoptin or Calan and dose forms like verapamil 80 mg and verapamil SR, reflecting brand familiarity in communities across Canada.

Community forums often highlight concerns about constipation, driving safety and interactions with other heart medicines.

Bilingual labelling in English and French is expected, and patients in Quebec or francophone households may request French product information and counselling.

• Common Patient Concerns: constipation, dizziness, dosing schedules and whether ER or IR is better for daily life.
• Practical Counselling Points: advise on bowel management strategies, warn about driving until effects are known, and confirm whether ER products are preferred for adherence.

Rural access issues: limited pharmacy hours, formulary variation and delayed specialist referrals mean telepharmacy or nurse‑practitioner clinics often manage initial titration and follow‑up.

Availability & Pricing Patterns

How easy is it for Canadian patients to get verapamil and what should they check at purchase?

Verapamil is prescription‑only and available through major chains and online Canadian pharmacies, with generics supplied by Viatris, Teva and others increasing availability in urban centres.

Rural stock can vary and provincial coverage determines whether a branded ER or a generic IR product is preferred by formularies.

Cross‑border pricing differences sometimes lead patients to consider bringing medication from the United States or using mail‑order, but import rules and DIN differences apply.

Purchase checklist: confirm DIN, valid prescription, formulary coverage and bilingual labelling at point of sale.

Note: in our online pharmacy, verampil is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

• Steps To Confirm Coverage: ask pharmacist to check ODB/PharmaCare/RAMQ listing, verify DIN on the bottle, and request prior authorization if needed.

Comparable Medicines And Preferences

Which agents are commonly chosen instead of verapamil, and why?

• Pros/Cons Checklist: verapamil is effective for SVT and AF rate control but carries higher constipation and conduction risks; diltiazem has similar efficacy with a different side‑effect profile; amlodipine is preferable for isolated hypertension without conduction issues.
• Clinical Preference Scenarios: avoid verapamil in known conduction disease or when the patient is already on high‑dose beta‑blockers.

Frequently Asked Questions — Patient‑Centred Q&A

Can I get verapamil without a prescription in Canada?

No, verapamil is prescription‑only in most territories, though check with your pharmacy for specific access programs and DIN details.

Will my provincial plan cover verapamil?

Coverage depends on eligibility and formulary listings such as ODB, BC PharmaCare or RAMQ; your pharmacist can verify coverage and DIN tracking at dispensing.

Is it safe to drive after starting verapamil?

Monitor for dizziness, lightheadedness or marked bradycardia and delay driving until you know how the medicine affects you.

What if I miss a dose?

Take the missed dose as soon as you remember unless it is almost time for the next dose; do not double the dose to catch up.

What are emergency signs of overdose?

Severe hypotension, marked bradycardia, confusion or collapse require emergency care; treatment may include intravenous fluids, vasopressors and calcium salts such as calcium gluconate.

• Quick Action Steps: stop the medicine if severe symptoms occur and proceed to the nearest emergency department or call emergency services.
• Bilingual Resources: ask your pharmacist for English and French product monographs and local health line contacts.

Guidelines For Proper Use — Pharmacist & Provincial Tips

How should pharmacists prepare and counsel when dispensing verapamil?

• Dispensing Checklist: confirm DIN, verify indication and dose form (IR vs ER), counsel on constipation management and hypotension risk, and screen for interacting meds including beta‑blockers, digoxin and CYP3A4 inhibitors.
• Storage Guidance: store tablets and capsules below 25°C, dry and protected from light; IV solutions should be protected from light and discarded if discoloured.

Provincial Tips: document rationale for off‑label use and submit prior authorization if required by the provincial drug plan; rural patients may prefer longer fills or home delivery through pharmacy chains.

• Baseline Monitoring: consider baseline ECG, check blood pressure and heart rate, and arrange follow‑up within 1–4 weeks after initiation or dose change.

When To Refer To Emergency Department: severe hypotension, syncope, severe bradycardia or any signs of cardiogenic shock.

Recommended Resources: consult Health Canada product monographs and provincial formulary portals for DIN and coverage details when in doubt.

Delivery Across Canada (English)